Advertisement

Search Results

Advertisement



Your search for all items matches 1601 pages

Showing 301 - 350


breast cancer

Andrew D. Seidman, MD, and Susan F. Dent, MD, on Breast Cancer: Analysis of the SANDPIPER Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings on taselisib plus fulvestrant vs fulvestrant in patients with estrogen receptor–positive, PIK3CA-mutant, locally advanced or metastatic ...

breast cancer

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Metastatic Breast Cancer: Findings on an Antibody-Drug Conjugate

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzumab govitecan for treatment-refractory hormone receptor–positive/HER2-negative metastatic breast cancer (Abstract 1004).

breast cancer

Michael Gnant, MD, on Breast Cancer: Results From the ABCSG-18 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal patients.

breast cancer

2018 ASCO: Neoadjuvant Use of PARP Inhibitor Shows Promise in Early-Stage, BRCA-Mutated Breast Cancer

In a small phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time...

breast cancer

2018 ASCO: Aromatase Inhibitor Plus Ovarian Suppression Yields Benefit in High-Risk Premenopausal Patients With Breast Cancer

Premenopausal women with hormone receptor (HR)­–positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain a 10% to 15% improvement in freedom from distant recurrence at 8 years, according to a ...

breast cancer

Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Breast Cancer: Commentary on the TAILORx Trial

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative,...

breast cancer
immunotherapy

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Results From the GeparNuevo Trial

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses phase II study findings on the addition of durvalumab to a taxane-anthracycline–containing chemotherapy in triple-negative breast cancer (Abstract 104).

breast cancer

Rebecca A. Dent, MD, on Triple-Negative Breast Cancer: Results From the LOTUS Trial

Rebecca A. Dent, MD, of the National Cancer Centre Singapore, discusses phase II study findings on first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-negative breast cancer (Abstract 1008).

breast cancer
immunotherapy

Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial

Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early breast cancer (Abstract 506).

breast cancer

Sherry Shen, MD, on Breast Cancer and Obesity: Results of the SWOG S0927 Study

Sherry Shen, MD, of Columbia University Medical Center, discusses findings on the use of omega-3 fatty acid for obese breast cancer patients with aromatase inhibitor–related arthralgia (Abstract 10000).

breast cancer

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).

breast cancer

Joseph A. Sparano, MD, on Breast Cancer: Results of the TAILORx Trial

Joseph A. Sparano, MD, of Montefiore Medical Center, discusses phase III study results on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score (Abstract LBA1).

breast cancer

2018 ASCO: TAILORx: Most Women With Early-Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test

The federally funded, phase III TAILORx clinical trial showed that most women with hormone receptor (HR)–positive, HER2-negative, axillary node–negative early-stage breast cancer and a mid-range score on a 21-tumor gene expression assay (Oncotype DX® Breast Recurrence Score) do not...

breast cancer

Gabriel N. Hortobagyi, MD, on Breast Cancer Staging: New and Important Changes

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.

breast cancer

2018 ASCO: Phase III SANDPIPER Trial Evaluates Taselisib Plus Fulvestrant in Advanced Breast Cancer

In a phase III clinical trial, the investigational PI3K inhibitor taselisib combined with standard hormone therapy fulvestrant (Faslodex) halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone. In addition, the novel combination decreased the chance of...

breast cancer

Multiple-Gene Sequencing vs BRCA1/2-Only Testing After Breast Cancer Diagnosis

In a retrospective cohort study reported in JAMA Oncology, Kurian et al found that use of germline multiple-gene sequencing has become more common than BRCA1/2-only sequencing after breast cancer diagnosis in clinical practice, with an associated increased detection of pathologic variants not...

breast cancer

Circulating Tumor Cells and Benefit of Adjuvant Radiotherapy in Early Breast Cancer

In a study reported in JAMA Oncology, Goodman et al found that adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable circulating tumor cells (CTCs). Study Details The analysis included data from patients with stage pT1 to pT2 and pN0 to...

breast cancer

Effect of GnRHa Treatment During Chemotherapy on Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer

A meta-analysis of patient-level data reported by Lambertini et al in the Journal of Clinical Oncology indicated that temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy was effective in preserving ovarian function and fertility in premenopausal...

breast cancer

Risk of Interval Invasive Second Breast Cancers

In a study reported in the Journal of Clinical Oncology, Lee et al determined risk levels for interval invasive second breast cancers after negative surveillance mammography and identified factors associated with higher risk.  Study Details The study involved 65,084 surveillance mammograms...

breast cancer

Risk of Breast Cancer After Negative Screening Mammography

In a study reported in JAMA Oncology, McCarthy et al identified the risk of interval breast cancer after negative screening mammography, including risk of poor-prognosis breast cancer. Study Details The study involved mammography data from the Population-Based Research Optimizing Screening...

breast cancer

CXCR4 Antagonist Plus Eribulin in HER2-Negative Metastatic Breast Cancer

Findings in a phase I trial reported in The Lancet Oncology by Pernas et al indicate activity of the combination of the CXCR4 chemokine receptor antagonist balixafortide plus eribulin in previously treated HER2-negative metastatic breast cancer. The CXCR4–stromal cell-derived factor-1α...

breast cancer
immunotherapy

2018 ASCO: Shortening Adjuvant Trastuzumab to 6 Months in Patients With HER2-Positive Early Breast Cancer Is Effective and Reduces Cardiac Toxicities

Persephone, a large phase III randomized noninferiority study conducted in the United Kingdom comparing 6 months to 12 months of trastuzumab (Herceptin) in patients with HER2-positive early breast cancer has found 6 months of trastuzumab to be noninferior to 12 months of the therapy. In addition,...

breast cancer

Sarcopenia, Adiposity, and Survival in Women With Nonmetastatic Breast Cancer

In a study reported in JAMA Oncology, Caan et al found that computed tomography (CT)-derived sarcopenia and adiposity were associated with overall survival in women with nonmetastatic breast cancer. Study Details The study involved data from 3,241 women from Kaiser Permanente of Northern...

breast cancer

Hormone Replacement Therapy and Breast Cancer Risk After Oophorectomy in BRCA1-Mutation Carriers

In a study reported in JAMA Oncology, Kotsopoulos et al found that use of hormone replacement therapy overall did not increase risk of breast cancer among BRCA1-mutation carriers after prophylactic bilateral salpingo-oophorectomy; however, use of estrogen-progesterone hormone replacement...

breast cancer

Predictive Model for Breast Cancer in Women With Atypical Hyperplasia

As reported in the Journal of Clinical Oncology, Degnim et al have developed a model for predicting breast cancer risk among women with atypical hyperplasia on breast biopsy. Study Details The risk model (AH-BC) was developed using retrospective cohorts of women aged 18 to 85 years with...

breast cancer

ASBrS 2018: Early Detection and Intervention Effective for Preventing Breast Cancer–Related Lymphedema

Early, ongoing screening of lymphatic function and immediate patient-administered therapies as needed are highly effective in improving outcomes for women at high risk for breast cancer–related lymphedema (BCRL). These were the findings of a new study presented at the American Society of ...

breast cancer

ASBrS 2018: Modern Therapies Minimize Recurrence After Breast-Conserving Surgery

Modern, multimodality lumpectomy treatment significantly reduces the incidence of breast cancer recurrence at the original tumor site compared to historical protocols, according to a new study presented at the American Society of Breast Surgeons (ASBrS) 19th Annual Meeting (Abstract...

breast cancer

ASBrS 2018: Breast Cancer Genetic Testing Guidelines Exclude Almost Half of High-Risk Patients

Current restrictive genetic testing guidelines exclude many patients who harbor high-risk breast cancer mutations, according to two new studies presented at the American Society of Breast Surgeons (ASBrS) 19th Annual Meeting (Abstracts 402910, 404340). One study found that whether or not patients...

breast cancer

ASBrS 2018: Regular Mammograms May Mean Earlier Breast Cancer Diagnosis and Less Aggressive Treatment

Women with breast cancer who underwent regular mammographic screening were diagnosed with earlier-stage disease and treated with significantly less aggressive therapies than those who delayed or never underwent screening, according to new research presented at the American Society of Breast...

breast cancer

Targeting Chemotherapy With Genetic Testing in Advanced Triple-Negative Breast Cancer

Researchers have found that women with advanced triple-negative breast cancer with a BRCA mutation were twice as likely to benefit from carboplatin as docetaxel—the current standard of care for these patients. These findings were published by Tutt et al in Nature Medicine. The trial is set...

breast cancer

Web-Based Writing Intervention for Body Image–Related Distress in Women With Breast Cancer

In an Australian trial reported in the Journal of Clinical Oncology, Sherman et al found that use of a structured online writing exercise (My Changed Body) was associated with reduced body image distress and improved body appreciation among breast cancer survivors. Study Details My Changed...

breast cancer
survivorship

Hormone Therapy and Diabetes Risk in Survivors of Breast Cancer

In an Israeli case-cohort study reported in the Journal of Clinical Oncology, Hamood et al found that hormone therapy in breast cancer survivors was associated with an increased risk of developing diabetes. The study involved a cohort of 2,246 women from the Leumit health-care fund diagnosed with...

breast cancer

Long-Term Quality-of-Life Results Compared for Two Radiotherapy Strategies After Breast-Conserving Surgery

As reported in The Lancet Oncology by Schäfer et al, little difference in quality of life was observed over long-term follow-up between women receiving accelerated partial-breast irradiation (APBI) with interstitial brachytherapy vs whole-breast irradiation (WBI) after breast-conserving...

breast cancer

Prediction of Late Distant Recurrence in Estrogen Receptor–Positive Breast Cancer After 5 Years of Endocrine Therapy

As reported in the Journal of Clinical Oncology, Dowsett et al have developed a clinicopathologic tool for predicting risk of late distant recurrence in estrogen receptor (ER)-positive breast cancer treated with 5 years of endocrine therapy. Study Details In the study, a prognostic score for...

breast cancer

New Breath and Urine Tests May Detect Early Breast Cancer More Accurately

A new method for early, more accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center using commercially available technology. Their findings were published by Herman-Saffar et al in Computers in Biology and...

breast cancer

Adverse Financial Impact of Breast Cancer for Black vs White Women

In a study reported in the Journal of Clinical Oncology, Wheeler et al found that black women experience significantly worse financial impact from breast cancer compared with white women, which may contribute to barriers to treatment compliance and worse outcomes. Study Details The...

breast cancer

Addition of Everolimus to Fulvestrant in HR-Positive, HER2-Negative, Aromatase Inhibitor–Resistant Metastatic Breast Cancer

In the phase II PrE0102 trial reported in the Journal of Clinical Oncology by Kornblum et al, the addition of everolimus to fulvestrant (Faslodex) improved progression-free survival in postmenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer resistant to...

breast cancer

Many Economic Evaluations of Oncotype DX May Have Misleading Conclusions

Research from the Yale School of Public Health has found that the majority of published papers analyzing the cost-effectiveness of a widely used test for breast cancer used a study design that can increase bias. These findings were published by Wang et al in the Journal of Clinical Oncology....

breast cancer

Family History and Contralateral Breast Cancer Risk in Young Women

In an update from the WECARE (Women’s Environmental Cancer and Radiation Epidemiology) study reported in the Journal of Clinical Oncology, Reiner et al found that women with invasive breast cancer are at increased risk of contralateral breast cancer even in the absence of deleterious...

breast cancer

FDA Grants Fast Track Designation for Balixafortide in Combination With Eribulin as Third-Line Therapy for Metastatic Breast Cancer

On April 19, Polyphor announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326) in combination with eribulin (Halaven) for the treatment of patients with HER2-negative metastatic breast cancer who...

breast cancer

mTOR Inhibitor Plus Endocrine Therapy in Postmenopausal Women With Advanced ER-Positive, HER2-Negative Breast Cancer

In the phase II BOLERO-4 trial reported in JAMA Oncology, Royce et al found that the combination of the mTOR inhibitor everolimus (Afinitor) and endocrine therapy was active in first-line treatment of postmenopausal women with advanced estrogen receptor (ER)-positive, human epidermal growth factor...

breast cancer

Cardiovascular Risk Factors, Cardiac Events, and Survival in Patients With Breast Cancer Enrolled in SWOG Clinical Trials

In a study reported in the Journal of Clinical Oncology, Hershman et al found that each additional baseline cardiovascular disease risk factor was associated with increased risk for cardiac events and death among Medicare patients who had been enrolled in SWOG trials in breast cancer. Study...

breast cancer

EBCC-11: Mastectomy and Axillary Dissection and Neoadjuvant Targeted Treatment in HER2-Positive Breast Cancer

Extensive surgery involving mastectomy and removal of several lymph nodes may be safely avoided for more women with some types of breast cancer if they receive targeted drugs before surgery, according to research presented at the 11th European Breast Cancer Conference (EBCC-11) (Abstract 19). The...

breast cancer

EBCC-11: Women Report Fewer Side Effects With Partial or Reduced Breast Radiotherapy vs Standard WBRT

The average number of moderate or marked side effects reported by patients with breast cancer is lower if they are treated with radiotherapy to part of the breast or a reduced dose to the whole breast, rather than with standard whole breast radiotherapy (WBRT), according to new findings presented...

breast cancer

EBCC-11: MINDACT Trial: Patients With Early Breast Cancer and Risk of Locoregional Recurrence

Women with small, low-grade, well-defined breast tumors and a genetic profile that shows they are at low risk of the cancer metastasizing have only a 1.4% risk of locoregional recurrence within 5 years, according to new results from a large randomized trial of nearly 7,000 patients. This low risk...

breast cancer

EBCC-11: Sentinel Lymph Node Biopsy in Triple-Negative and HER2-Positive Breast Cancers

Sentinel lymph node biopsies may be safely avoided for some women, according to research presented at the 11th European Breast Cancer Conference (EBCC-11). Two new studies show that women with either triple-negative or HER2-positive types of breast cancer, whose cancers respond well to chemotherapy ...

breast cancer

EBCC-11: Double Mastectomy in BRCA1 and BRCA2 Carriers

Healthy women who carry a breast cancer–causing mutation in the BRCA1 gene not only reduce their risk of developing the disease but also their chances of dying from it if they have both breasts removed, according to new research presented at the 11th European Breast Cancer Conference...

breast cancer

EBCC-11: DCIS Less Likely to Recur in Patients Who Are Postmenopausal, ER-Positive

Patients with ductal carcinoma in situ (DCIS) are less likely to have recurrent disease if they are postmenopausal or if their tumor is estrogen receptor (ER)-positive, according to research presented at the 11th European Breast Cancer Conference (EBCC-11) (Abstract 215). DCIS accounts for about...

breast cancer

EBCC-11: Risk of a Second Breast Cancer Can Be Better Quantified in Patients With a BRCA Mutation

The risk of a second breast cancer in patients with high-risk BRCA gene mutations can be more precisely predicted by testing for several other genetic variants, each of which are known to have a small impact on breast cancer risk, according to new research presented at the 11th European Breast...

breast cancer

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved olaparib for gBRCA-mutant breast cancer.

Advertisement

Advertisement



Advertisement